ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CHIKV VLP vaccine

Its studies are mostly in Chikungunya Fever, led by Bavarian Nordic.

Furthest: phase 3, since May 27, 20252 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bavarian Nordic22 open or runningphase 3since May 27, 2025May 27, 2025Sep 2028phase 3 · NCT07003984

Also a collaborator on its studies: Pharmaceutical Product Development, (PPD) and Q-square Business Intelligence.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2025First study: phase 3 study in Chikungunya FeverFirst studyNCT07003984 · 720 enrolled · United States, Philippines, Puerto Rico
  2. Mar 9, 2026Phase 3 study in Chikungunya FeverNCT07467707 · 6,144 planned · Philippines, Thailand

Ahead

  1. Sep 2028Primary completion: phase 3 study in Chikungunya FeverNCT07003984
  2. May 2030Primary completion: phase 3 study in Chikungunya FeverNCT07467707

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“CHIKV VLP vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07467707Chikungunya Fever · Philippines, Thailand3RecruitingMay 20306,144
NCT07003984Chikungunya Fever · United States, Philippines, Puerto Rico3Active, not recruitingSep 2028720

How it is read

Names in the registry

  • “CHIKV VLP vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.